Importantly, simultaneous administration of palbociclib and cisplatin intraperitoneally significantly inhibited tumor growth in the IGF2BP3 overexpression group, indicating that palbociclib could improve sensitivity to cisplatin chemotherapy Figure S7A-C). Here, IGF2BP3 is linked to neoplasm.